Image source: Shutterstock

Highlights

  • Lacutamab granted FDA Breakthrough Therapy Designation for relapsed or refractory Sézary syndrome.

  • First patient dosed in a Phase 1 study for IPH4502, a Nectin-4 ADC targeting advanced solid tumors.

  • €91.1 million cash position as of December 31, 2024, with funding secured through mid-2026.

Innate Pharma SA (Nasdaq:IPHA) has announced its financial results for the year ending December 31, 2024, alongside notable advancements in its clinical pipeline. The company continues to make progress in immuno-oncology, securing regulatory recognition and funding to support ongoing research efforts.

Pipeline Progress and Regulatory Milestones

A significant milestone for Innate Pharma in 2024 was the FDA Breakthrough Therapy Designation for lacutamab, a treatment for relapsed or refractory Sézary syndrome, a rare and aggressive form of cutaneous T-cell lymphoma. This designation is expected to accelerate the development and review process, providing potential benefits for patients in need of new treatment options.

New data from the TELLOMAK Phase 2 study, presented at ASH 2024, highlighted lacutamab’s potential in improving health-related quality of life for patients with cutaneous T-cell lymphoma. These findings reinforce its therapeutic promise and support ongoing clinical evaluations.

Meanwhile, the first patient has been dosed in the Phase 1 trial for IPH4502, a Nectin-4 antibody-drug conjugate (ADC) designed to treat advanced solid tumors. Additionally, IPH6501, part of Innate’s ANKET® platform, is progressing through a Phase 1/2 trial for patients with B-cell non-Hodgkin’s lymphoma, a key area of focus in hematologic oncology.

Strategic Investment and Financial Stability

Innate Pharma’s pipeline expansion received further backing with a $7.9 million investment from the Institute for Follicular Lymphoma Innovation (IFLI). These funds will support the development of IPH6501 in Follicular Lymphoma.

From a financial perspective, Innate reported a cash position of €91.1 million as of December 31, 2024. This stable financial footing extends the company’s operational runway through mid-2026, ensuring continued investment in research, development, and clinical trials.